Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04381130 | A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Everfront Biotech Co., Ltd.INDUSTRY | 0 | Sep 11, 2026 | clinicaltrials |
| NCT05095948 | Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center | not yet recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07104253 | Establishing Feasibility of Transbronchial Cryoablation With an In-Development Cryoprobe: An Ex-Vivo Human Lung Model | not yet recruiting | N/A | 10 | Endocision Technologies Inc.INDUSTRY | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07279948 | Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)(LUSIP) | not yet recruiting | — | 477 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07527325 | Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma | not yet recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07575685 | Enhancing Cancer Care: RestoreMe App for Personalized Nutrition and Activity in Cancer Patients(RestoreMe) | not yet recruiting | N/A | 150 | Montefiore Medical CenterOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07593079 | Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer | not yet recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07651267 | Financial Toxicity, Quality of Life, and Psychological Resources in Breast Cancer Survivors : A Longitudinal Study(FTQoL-BC) | not yet recruiting | — | 160 | Okayama UniversityOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07674823 | Study Of KITE-753 in R/R B-Cell ALL | not yet recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Grit BiotechnologyINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07700758 | A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) | not yet recruiting | Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07729384 | Strengthening Teen Brain Resilience Using Music Intervention to Improve Radiation Induced Cognitive Decline for Adolescents Undergoing Radiation Therapy for Cancer Treatment | not yet recruiting | N/A | 30 | Mayo ClinicOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07743164 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) | not yet recruiting | Phase 3 | 646 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07764744 | Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants(OC-LEAD) | not yet recruiting | N/A | 70 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07767448 | Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events | not yet recruiting | N/A | 50 | Stanford UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07799740 | Examination of Rectal Blood Supply During Rectal Cancer Surgery Using Laser Speckle Contrast Imaging(LIRA) | not yet recruiting | N/A | 100 | University of AarhusOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07810400 | A Study Of Remote Patient Monitoring (RPM) Program For Cancer Patients Initiating Cancer-directed Therapy | not yet recruiting | N/A | 470 | Mayo ClinicOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814560 | Metabolic Syndrome and Risk of Chronic Philadelphia Negative Myeloproliferative Neoplasms(MetSaMyeloprof) | not yet recruiting | — | 313 | Assiut UniversityOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07814586 | Prognostic Evaluation and Systematic Re-Assessment of Cholangiocarcinoma Therapy(Re-ACT) | not yet recruiting | — | 900 | Karolinska University HospitalOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07814859 | Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer | not yet recruiting | Phase 2 | 88 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815054 | Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical | not yet recruiting | — | 200 | The First Hospital of Jilin UniversityOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07815093 | Multimodal Artificial Intelligence for Non-Invasive Colorectal Cancer Screening Based on Holographic Biology | not yet recruiting | — | 11,000 | Xiuli ZuoOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07815197 | Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer(PERSEUS) | not yet recruiting | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815574 | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma(SCOPE Plus) | not yet recruiting | Phase 3 | 550 | Scancell LtdINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | not yet recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815912 | Smoking Relapse Prevention in Patients With Cancer | not yet recruiting | N/A | 498 | Vietnam National Cancer HospitalINDIV | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07090109 | PITCH - Impacting Hereditary Cancer Testing | not yet recruiting | N/A | 200 | Rachel MillerOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07349693 | Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma(Cerebraca-02/3) | not yet recruiting | Phase 2 / Phase 3 | 175 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07374796 | Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer | not yet recruiting | — | 450 | University of Maryland, BaltimoreOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07513324 | Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) | not yet recruiting | Phase 2 | 116 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07605949 | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML(RAVEN) | not yet recruiting | Phase 2 | 88 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07623187 | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy(EVICTION 3) | not yet recruiting | Phase 2 / Phase 3 | 540 | IpsenINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | not yet recruiting | N/A | 300 | Ossium Health, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07733427 | Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer(PIT) | not yet recruiting | N/A | 40 | Clinique BizetOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07776964 | Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) | not yet recruiting | N/A | 72 | University of MinnesotaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07799194 | Percutaneous Pulsed Electric Field Ablation for Early-Stage NSCLC and Lung Oligometastases: A Safety and Efficacy Study | not yet recruiting | N/A | 10 | Energenx Medical LTD.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07799220 | A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811258 | Improving Adherence to Chronic Disease Medication Regimens Among Patients With Recently Diagnosed Cancer: A Pilot Study | not yet recruiting | N/A | 30 | Duke UniversityOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | not yet recruiting | Phase 3 | 600 | BeOne MedicinesINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811453 | Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options(GTO-001) | not yet recruiting | N/A | 260 | Charite University, Berlin, GermanyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811739 | Brief Mindfulness Chatbot Intervention for Cancer Patients(MINDBOT-CA) | not yet recruiting | N/A | 66 | Taipei Medical UniversityOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07811986 | HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease(BEYOND-MM 001) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812207 | Right Ventricular Afterload Indices in Lung Surgery(RAILS) | not yet recruiting | — | 15 | University of GlasgowOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07812246 | Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial | not yet recruiting | Phase 2 | 44 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812467 | Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials